Recent submissions
Now showing items 41-60 of 676
-
Impact of pharmacogenomic DPYD variant guided dosing on toxicity in patients receiving fluoropyrimidines for gastrointestinal cancers in a high-volume tertiary centre.
(BMC, 2023-04-26)BACKGROUND: Dihydropyrimidine dehydrogenase (DPD) is a key enzyme in the metabolism of fluoropyrimidines. Variations in the encoding DPYD gene are associated with severe fluoropyrimidine toxicity and up-front dose reductions ... -
MND1 and PSMC3IP control PARP inhibitor sensitivity in mitotic cells.
(CELL PRESS, 2023-05-30)The PSMC3IP-MND1 heterodimer promotes meiotic D loop formation before DNA strand exchange. In genome-scale CRISPR-Cas9 mutagenesis and interference screens in mitotic cells, depletion of PSMC3IP or MND1 causes sensitivity ... -
Molecular profiling of aromatase inhibitor sensitive and resistant ER+HER2- postmenopausal breast cancers.
(NATURE PORTFOLIO, 2023-07-07)Aromatase inhibitors (AIs) reduce recurrences and mortality in postmenopausal patients with oestrogen receptor positive (ER+) breast cancer (BC), but >20% of patients will eventually relapse. Given the limited understanding ... -
The proteomic landscape of soft tissue sarcomas.
(NATURE PORTFOLIO, 2023-06-29)Soft tissue sarcomas (STS) are rare and diverse mesenchymal cancers with limited treatment options. Here we undertake comprehensive proteomic profiling of tumour specimens from 321 STS patients representing 11 histological ... -
Circulating vitamin D and breast cancer risk: an international pooling project of 17 cohorts.
(SPRINGER, 2023-01-01)Laboratory and animal research support a protective role for vitamin D in breast carcinogenesis, but epidemiologic studies have been inconclusive. To examine comprehensively the relationship of circulating 25-hydroxyvitamin ... -
Age-associated microenvironmental changes highlight the role of PDGF-C in ER+ breast cancer metastatic relapse.
(NATURE PORTFOLIO, 2023-04-01)Patients with estrogen receptor (ER)-positive breast cancer are at risk of metastatic relapse for decades after primary tumor resection and treatment, a consequence of dormant disseminated tumor cells (DTCs) reawakening ... -
TGFβ-mediated MMP13 secretion drives myoepithelial cell dependent breast cancer progression.
(NATURE PORTFOLIO, 2023-03-02)Ductal carcinoma in situ (DCIS) is a non-obligate precursor of invasive breast cancer. Virtually all women with DCIS are treated, despite evidence suggesting up to half would remain with stable, non-threatening, disease. ... -
Design of SERENA-6, a phase III switching trial of camizestrant in ESR1-mutant breast cancer during first-line treatment.
(FUTURE MEDICINE LTD, 2023-03-01)ESR1 mutation (ESR1m) is a frequent cause of acquired resistance to aromatase inhibitor (AI) plus cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i), which is a first-line therapy for hormone-receptor-positive (HR+)/human ... -
Utility of polygenic risk scores in UK cancer screening: a modelling analysis.
(ELSEVIER SCIENCE INC, 2023-05-10)BACKGROUND: It is proposed that, through restriction to individuals delineated as high risk, polygenic risk scores (PRSs) might enable more efficient targeting of existing cancer screening programmes and enable extension ... -
Late-Stage Metastatic Melanoma Emerges through a Diversity of Evolutionary Pathways.
(AMER ASSOC CANCER RESEARCH, 2023-06-02)UNLABELLED: Understanding the evolutionary pathways to metastasis and resistance to immune-checkpoint inhibitors (ICI) in melanoma is critical for improving outcomes. Here, we present the most comprehensive intrapatient ... -
Predicting Response to Radical Chemoradiotherapy with Circulating HPV DNA (cHPV-DNA) in Locally Advanced Uterine Cervix Cancer.
(MDPI, 2023-02-22)BACKGROUND: The majority of locally advanced cervical cancers (LaCC) are causally related to HPV. We sought to investigate the utility of an ultra-sensitive HPV-DNA next generation sequencing (NGS) assay-panHPV-detect-in ... -
Generating patient-derived models of soft-tissue sarcoma for the evaluation of therapy response and resistance
(Institute of Cancer Research (University Of London), 2023-05-04)For the majority of patients, advanced soft-tissue sarcoma (STS) is fatal, with an overall survival of 14-19 months. Systemic chemotherapy has remained the cornerstone of advanced STS control for more than 30 years and ... -
CCNE1 and PLK1 Mediate Resistance to Palbociclib in HR+/HER2- Metastatic Breast Cancer.
(AMER ASSOC CANCER RESEARCH, 2023-04-14)PURPOSE: In hormone receptor-positive (HR+)/HER2- metastatic breast cancer (MBC), it is imperative to identify patients who respond poorly to cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) and to discover therapeutic ... -
Novel biochemical, structural, and systems insights into inflammatory signaling revealed by contextual interaction proteomics.
(NATL ACAD SCIENCES, 2022-10-04)Protein-protein interactions (PPIs) represent the main mode of the proteome organization in the cell. In the last decade, several large-scale representations of PPI networks have captured generic aspects of the functional ... -
Next-Generation Sequencing and Image-Guided Tissue Sampling: A Primer for Interventional Radiologists.
(Elsevier BV, 2023-03-01)The discovery of increasing numbers of actionable molecular and gene targets for cancer treatment has driven the demand for tissue sampling for next-generation sequencing (NGS). Requirements for sequencing can be very ... -
CCNE1 and survival of patients with tubo-ovarian high-grade serous carcinoma: An Ovarian Tumor Tissue Analysis consortium study.
(WILEY, 2023-03-01)BACKGROUND: Cyclin E1 (CCNE1) is a potential predictive marker and therapeutic target in tubo-ovarian high-grade serous carcinoma (HGSC). Smaller studies have revealed unfavorable associations for CCNE1 amplification and ... -
Targeting the Progesterone Receptor in Breast Cancer: Mind the Short Form!
(AMER ASSOC CANCER RESEARCH, 2023-03-01)The presurgical window of opportunity trial (WOT) MIPRA provides evidence that neoadjuvant treatment with the progesterone receptor (PR) antagonist mifepristone (RU486) may benefit patients with estrogen receptor-positive ... -
Elacestrant demonstrates strong anti-estrogenic activity in PDX models of estrogen-receptor positive endocrine-resistant and fulvestrant-resistant breast cancer.
(NATURE PORTFOLIO, 2022-11-29)The selective oestrogen receptor (ER) degrader (SERD), fulvestrant, is limited in its use for the treatment of breast cancer (BC) by its poor oral bioavailability. Comparison of the orally bioavailable investigational SERD ... -
Identification of genetic determinants of ATR inhibitor sensitivity in ARID1A mutant ovarian clear cell carcinoma
(Institute of Cancer Research (University Of London), 2023-01-23)Ovarian clear cell carcinoma (OCCC) is a gynaecological cancer of unmet need characterized by ARID1A and PPP2R1A mutations. Prior work identified a synthetic lethality between ARID1A tumour suppressor mutations in OCCC and ... -
Endo180 (MRC2) Antibody-Drug Conjugate for the Treatment of Sarcoma.
(AMER ASSOC CANCER RESEARCH, 2023-02-01)Although the 5-year survival rates for sarcoma patients have improved, the proportion of patients relapsing after first-line treatment remains high, and the survival of patients with metastatic disease is dismal. Moreover, ...